

SECOND REGULAR SESSION

HOUSE BILL NO. 2054

97TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVES COLONA (Sponsor), HIGDON AND CURTMAN (Co-sponsors).

6165H.02I

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal sections 195.010, 195.017, and 195.202, RSMo, and to enact in lieu thereof seven new sections relating to industrial hemp, with existing penalty provisions.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Sections 195.010, 195.017, and 195.202, RSMo, are repealed and seven new sections enacted in lieu thereof, to be known as sections 195.010, 195.017, 195.202, 195.203, 195.600, 195.603, and 195.606, to read as follows:

195.010. The following words and phrases as used in sections 195.005 to 195.425, unless the context otherwise requires, mean:

(1) "Addict", a person who habitually uses one or more controlled substances to such an extent as to create a tolerance for such drugs, and who does not have a medical need for such drugs, or who is so far addicted to the use of such drugs as to have lost the power of self-control with reference to his addiction;

(2) "Administer", to apply a controlled substance, whether by injection, inhalation, ingestion, or any other means, directly to the body of a patient or research subject by:

(a) A practitioner (or, in his presence, by his authorized agent); or

(b) The patient or research subject at the direction and in the presence of the practitioner;

(3) "Agent", an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman while acting in the usual and lawful course of the carrier's or warehouseman's business;

(4) "Attorney for the state", any prosecuting attorney, circuit attorney, or attorney general authorized to investigate, commence and prosecute an action under sections 195.005 to 195.425;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

17 (5) "Controlled substance", a drug, substance, or immediate precursor in Schedules I
18 through V listed in sections 195.005 to 195.425;

19 (6) "Controlled substance analogue", a substance the chemical structure of which is
20 substantially similar to the chemical structure of a controlled substance in Schedule I or II and:

21 (a) Which has a stimulant, depressant, or hallucinogenic effect on the central nervous
22 system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central
23 nervous system of a controlled substance included in Schedule I or II; or

24 (b) With respect to a particular individual, which that individual represents or intends
25 to have a stimulant, depressant, or hallucinogenic effect on the central nervous system
26 substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous
27 system of a controlled substance included in Schedule I or II. The term does not include a
28 controlled substance; any substance for which there is an approved new drug application; any
29 substance for which an exemption is in effect for investigational use, for a particular person,
30 under Section 505 of the federal Food, Drug and Cosmetic Act (21 U.S.C. 355) to the extent
31 conduct with respect to the substance is pursuant to the exemption; or any substance to the extent
32 not intended for human consumption before such an exemption takes effect with respect to the
33 substance;

34 (7) "Counterfeit substance", a controlled substance which, or the container or labeling
35 of which, without authorization, bears the trademark, trade name, or other identifying mark,
36 imprint, number or device, or any likeness thereof, of a manufacturer, distributor, or dispenser
37 other than the person who in fact manufactured, distributed, or dispensed the substance;

38 (8) "Deliver" or "delivery", the actual, constructive, or attempted transfer from one
39 person to another of drug paraphernalia or of a controlled substance, or an imitation controlled
40 substance, whether or not there is an agency relationship, and includes a sale;

41 (9) "Dentist", a person authorized by law to practice dentistry in this state;

42 (10) "Depressant or stimulant substance":

43 (a) A drug containing any quantity of barbituric acid or any of the salts of barbituric acid
44 or any derivative of barbituric acid which has been designated by the United States Secretary of
45 Health and Human Services as habit forming under 21 U.S.C. 352(d);

46 (b) A drug containing any quantity of:

47 a. Amphetamine or any of its isomers;

48 b. Any salt of amphetamine or any salt of an isomer of amphetamine; or

49 c. Any substance the United States Attorney General, after investigation, has found to
50 be, and by regulation designated as, habit forming because of its stimulant effect on the central
51 nervous system;

52 (c) Lysergic acid diethylamide; or

53 (d) Any drug containing any quantity of a substance that the United States Attorney
54 General, after investigation, has found to have, and by regulation designated as having, a
55 potential for abuse because of its depressant or stimulant effect on the central nervous system or
56 its hallucinogenic effect;

57 (11) "Dispense", to deliver a narcotic or controlled dangerous drug to an ultimate user
58 or research subject by or pursuant to the lawful order of a practitioner including the prescribing,
59 administering, packaging, labeling, or compounding necessary to prepare the substance for such
60 delivery. "Dispenser" means a practitioner who dispenses;

61 (12) "Distribute", to deliver other than by administering or dispensing a controlled
62 substance;

63 (13) "Distributor", a person who distributes;

64 (14) "Drug":

65 (a) Substances recognized as drugs in the official United States Pharmacopoeia, Official
66 Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
67 supplement to any of them;

68 (b) Substances intended for use in the diagnosis, cure, mitigation, treatment or
69 prevention of disease in humans or animals;

70 (c) Substances, other than food, intended to affect the structure or any function of the
71 body of humans or animals; and

72 (d) Substances intended for use as a component of any article specified in this
73 subdivision. It does not include devices or their components, parts or accessories;

74 (15) "Drug-dependent person", a person who is using a controlled substance and who
75 is in a state of psychic or physical dependence, or both, arising from the use of such substance
76 on a continuous basis. Drug dependence is characterized by behavioral and other responses
77 which include a strong compulsion to take the substance on a continuous basis in order to
78 experience its psychic effects or to avoid the discomfort caused by its absence;

79 (16) "Drug enforcement agency", the Drug Enforcement Administration in the United
80 States Department of Justice, or its successor agency;

81 (17) "Drug paraphernalia", all equipment, products, substances and materials of any kind
82 which are used, intended for use, or designed for use, in planting, propagating, cultivating,
83 growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing,
84 storing, containing, concealing, injecting, ingesting, inhaling, or otherwise introducing into the
85 human body a controlled substance or an imitation controlled substance in violation of sections
86 195.005 to 195.425. It includes, but is not limited to:

87 (a) Kits used, intended for use, or designed for use in planting, propagating, cultivating,
88 growing or harvesting of any species of plant which is a controlled substance or from which a
89 controlled substance can be derived;

90 (b) Kits used, intended for use, or designed for use in manufacturing, compounding,
91 converting, producing, processing, or preparing controlled substances or imitation controlled
92 substances;

93 (c) Isomerization devices used, intended for use, or designed for use in increasing the
94 potency of any species of plant which is a controlled substance or an imitation controlled
95 substance;

96 (d) Testing equipment used, intended for use, or designed for use in identifying, or in
97 analyzing the strength, effectiveness or purity of controlled substances or imitation controlled
98 substances;

99 (e) Scales and balances used, intended for use, or designed for use in weighing or
100 measuring controlled substances or imitation controlled substances;

101 (f) Dilutents and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose
102 and lactose, used, intended for use, or designed for use in cutting controlled substances or
103 imitation controlled substances;

104 (g) Separation gins and sifters used, intended for use, or designed for use in removing
105 twigs and seeds from, or in otherwise cleaning or refining, marijuana;

106 (h) Blenders, bowls, containers, spoons and mixing devices used, intended for use, or
107 designed for use in compounding controlled substances or imitation controlled substances;

108 (i) Capsules, balloons, envelopes and other containers used, intended for use, or designed
109 for use in packaging small quantities of controlled substances or imitation controlled substances;

110 (j) Containers and other objects used, intended for use, or designed for use in storing or
111 concealing controlled substances or imitation controlled substances;

112 (k) Hypodermic syringes, needles and other objects used, intended for use, or designed
113 for use in parenterally injecting controlled substances or imitation controlled substances into the
114 human body;

115 (l) Objects used, intended for use, or designed for use in ingesting, inhaling, or otherwise
116 introducing marijuana, cocaine, hashish, or hashish oil into the human body, such as:

117 a. Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without screens,
118 permanent screens, hashish heads, or punctured metal bowls;

119 b. Water pipes;

120 c. Carburetion tubes and devices;

121 d. Smoking and carburetion masks;

- 122 e. Roach clips meaning objects used to hold burning material, such as a marijuana
123 cigarette, that has become too small or too short to be held in the hand;
- 124 f. Miniature cocaine spoons and cocaine vials;
- 125 g. Chamber pipes;
- 126 h. Carburetor pipes;
- 127 i. Electric pipes;
- 128 j. Air-driven pipes;
- 129 k. Chillums;
- 130 l. Bongs;
- 131 m. Ice pipes or chillers;
- 132 (m) Substances used, intended for use, or designed for use in the manufacture of a
133 controlled substance; In determining whether an object, product, substance or material is drug
134 paraphernalia, a court or other authority should consider, in addition to all other logically
135 relevant factors, the following:
- 136 a. Statements by an owner or by anyone in control of the object concerning its use;
- 137 b. Prior convictions, if any, of an owner, or of anyone in control of the object, under any
138 state or federal law relating to any controlled substance or imitation controlled substance;
- 139 c. The proximity of the object, in time and space, to a direct violation of sections
140 195.005 to 195.425;
- 141 d. The proximity of the object to controlled substances or imitation controlled
142 substances;
- 143 e. The existence of any residue of controlled substances or imitation controlled
144 substances on the object;
- 145 f. Direct or circumstantial evidence of the intent of an owner, or of anyone in control of
146 the object, to deliver it to persons who he knows, or should reasonably know, intend to use the
147 object to facilitate a violation of sections 195.005 to 195.425; the innocence of an owner, or of
148 anyone in control of the object, as to direct violation of sections 195.005 to 195.425 shall not
149 prevent a finding that the object is intended for use, or designed for use as drug paraphernalia;
- 150 g. Instructions, oral or written, provided with the object concerning its use;
- 151 h. Descriptive materials accompanying the object which explain or depict its use;
- 152 i. National or local advertising concerning its use;
- 153 j. The manner in which the object is displayed for sale;
- 154 k. Whether the owner, or anyone in control of the object, is a legitimate supplier of like
155 or related items to the community, such as a licensed distributor or dealer of tobacco products;
- 156 l. Direct or circumstantial evidence of the ratio of sales of the object to the total sales of
157 the business enterprise;

- 158 m. The existence and scope of legitimate uses for the object in the community;
- 159 n. Expert testimony concerning its use;
- 160 o. The quantity, form or packaging of the product, substance or material in relation to
161 the quantity, form or packaging associated with any legitimate use for the product, substance or
162 material;
- 163 (18) "Federal narcotic laws", the laws of the United States relating to controlled
164 substances;
- 165 (19) "Hospital", a place devoted primarily to the maintenance and operation of facilities
166 for the diagnosis, treatment or care, for not less than twenty-four hours in any week, of three or
167 more nonrelated individuals suffering from illness, disease, injury, deformity or other abnormal
168 physical conditions; or a place devoted primarily to provide, for not less than twenty-four
169 consecutive hours in any week, medical or nursing care for three or more nonrelated individuals.
170 The term "hospital" does not include convalescent, nursing, shelter or boarding homes as defined
171 in chapter 198;
- 172 (20) "Immediate precursor", a substance which:
- 173 (a) The state department of health and senior services has found to be and by rule
174 designates as being the principal compound commonly used or produced primarily for use in the
175 manufacture of a controlled substance;
- 176 (b) Is an immediate chemical intermediary used or likely to be used in the manufacture
177 of a controlled substance; and
- 178 (c) The control of which is necessary to prevent, curtail or limit the manufacture of the
179 controlled substance;
- 180 (21) "Imitation controlled substance", a substance that is not a controlled substance,
181 which by dosage unit appearance (including color, shape, size and markings), or by
182 representations made, would lead a reasonable person to believe that the substance is a controlled
183 substance. In determining whether the substance is an imitation controlled substance the court
184 or authority concerned should consider, in addition to all other logically relevant factors, the
185 following:
- 186 (a) Whether the substance was approved by the federal Food and Drug Administration
187 for over-the-counter (nonprescription or nonlegend) sales and was sold in the federal Food and
188 Drug Administration approved package, with the federal Food and Drug Administration
189 approved labeling information;
- 190 (b) Statements made by an owner or by anyone else in control of the substance
191 concerning the nature of the substance, or its use or effect;
- 192 (c) Whether the substance is packaged in a manner normally used for illicit controlled
193 substances;

194 (d) Prior convictions, if any, of an owner, or anyone in control of the object, under state
195 or federal law related to controlled substances or fraud;

196 (e) The proximity of the substances to controlled substances;

197 (f) Whether the consideration tendered in exchange for the noncontrolled substance
198 substantially exceeds the reasonable value of the substance considering the actual chemical
199 composition of the substance and, where applicable, the price at which over-the-counter
200 substances of like chemical composition sell. An imitation controlled substance does not include
201 a placebo or registered investigational drug either of which was manufactured, distributed,
202 possessed or delivered in the ordinary course of professional practice or research;

203 (22) **"Industrial hemp":**

204 (a) **All non-seed parts and varieties of the Cannabis Sativa plant, growing or not,**
205 **that contain a crop-wide average tetrahydrocannabinol (THC) concentration that does not**
206 **exceed three-tenths of one percent on a dry weight basis; or**

207 (b) **Any Cannabis Sativa seed that is part of a growing crop, retained by a grower**
208 **for future planting, or used for processing into or use as agricultural hemp seed; and**

209 (c) **Shall not include industrial hemp commodities and products;**

210 (23) "Laboratory", a laboratory approved by the department of health and senior services
211 as proper to be entrusted with the custody of controlled substances but does not include a
212 pharmacist who compounds controlled substances to be sold or dispensed on prescriptions;

213 [(23)] (24) "Manufacture", the production, preparation, propagation, compounding or
214 processing of drug paraphernalia or of a controlled substance, or an imitation controlled
215 substance, either directly or by extraction from substances of natural origin, or independently by
216 means of chemical synthesis, or by a combination of extraction and chemical synthesis, and
217 includes any packaging or repackaging of the substance or labeling or relabeling of its container.
218 This term does not include the preparation or compounding of a controlled substance or an
219 imitation controlled substance or the preparation, compounding, packaging or labeling of a
220 narcotic or dangerous drug:

221 (a) By a practitioner as an incident to his administering or dispensing of a controlled
222 substance or an imitation controlled substance in the course of his professional practice, or

223 (b) By a practitioner or his authorized agent under his supervision, for the purpose of,
224 or as an incident to, research, teaching or chemical analysis and not for sale;

225 [(24)] (25) "Marijuana", all parts of the plant genus Cannabis in any species or form
226 thereof, including, but not limited to Cannabis Sativa L., **except industrial hemp as defined in**
227 **this section**, Cannabis Indica, Cannabis Americana, Cannabis Ruderalis, and Cannabis Gigantea,
228 whether growing or not, the seeds thereof, the resin extracted from any part of the plant; and
229 every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or

230 resin. It does not include the mature stalks of the plant, fiber produced from the stalks, oil or
231 cake made from the seeds of the plant, any other compound, manufacture, salt, derivative,
232 mixture or preparation of the mature stalks (except the resin extracted therefrom), fiber, oil or
233 cake, or the sterilized seed of the plant which is incapable of germination;

234 [(25)] **(26)** "Methamphetamine precursor drug", any drug containing ephedrine,
235 pseudoephedrine, phenylpropanolamine, or any of their salts, optical isomers, or salts of optical
236 isomers;

237 [(26)] **(27)** "Narcotic drug", any of the following, whether produced directly or indirectly
238 by extraction from substances of vegetable origin, or independently by means of chemical
239 synthesis, or by a combination of extraction and chemical analysis:

240 (a) Opium, opiate, and any derivative, of opium or opiate, including their isomers, esters,
241 ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers,
242 esters, ethers, and salts is possible within the specific chemical designation. The term does not
243 include the isoquinoline alkaloids of opium;

244 (b) Coca leaves, but not including extracts of coca leaves from which cocaine, ecgonine,
245 and derivatives of ecgonine or their salts have been removed;

246 (c) Cocaine or any salt, isomer, or salt of isomer thereof;

247 (d) Ecgonine, or any derivative, salt, isomer, or salt of isomer thereof;

248 (e) Any compound, mixture, or preparation containing any quantity of any substance
249 referred to in paragraphs (a) to (d) of this subdivision;

250 [(27)] **(28)** "Official written order", an order written on a form provided for that purpose
251 by the United States Commissioner of Narcotics, under any laws of the United States making
252 provision therefor, if such order forms are authorized and required by federal law, and if no such
253 order form is provided, then on an official form provided for that purpose by the department of
254 health and senior services;

255 [(28)] **(29)** "Opiate", any substance having an addiction-forming or addiction-sustaining
256 liability similar to morphine or being capable of conversion into a drug having addiction-forming
257 or addiction-sustaining liability. The term includes its racemic and levorotatory forms. It does
258 not include, unless specifically controlled under section 195.017, the dextrorotatory isomer of
259 3-methoxy-n-methyl-morphinan and its salts (dextromethorphan);

260 [(29)] **(30)** "Opium poppy", the plant of the species *Papaver somniferum* L., except its
261 seeds;

262 [(30)] **(31)** "Over-the-counter sale", a retail sale licensed pursuant to chapter 144 of a
263 drug other than a controlled substance;

264 [(31)] (32) "Person", an individual, corporation, government or governmental
265 subdivision or agency, business trust, estate, trust, partnership, joint venture, association, or any
266 other legal or commercial entity;

267 [(32)] (33) "Pharmacist", a licensed pharmacist as defined by the laws of this state, and
268 where the context so requires, the owner of a store or other place of business where controlled
269 substances are compounded or dispensed by a licensed pharmacist; but nothing in sections
270 195.005 to 195.425 shall be construed as conferring on a person who is not registered nor
271 licensed as a pharmacist any authority, right or privilege that is not granted to him by the
272 pharmacy laws of this state;

273 [(33)] (34) "Poppy straw", all parts, except the seeds, of the opium poppy, after mowing;

274 [(34)] (35) "Possessed" or "possessing a controlled substance", a person, with the
275 knowledge of the presence and nature of a substance, has actual or constructive possession of
276 the substance. A person has actual possession if he has the substance on his person or within
277 easy reach and convenient control. A person who, although not in actual possession, has the
278 power and the intention at a given time to exercise dominion or control over the substance either
279 directly or through another person or persons is in constructive possession of it. Possession may
280 also be sole or joint. If one person alone has possession of a substance possession is sole. If two
281 or more persons share possession of a substance, possession is joint;

282 [(35)] (36) "Practitioner", a physician, dentist, optometrist, podiatrist, veterinarian,
283 scientific investigator, pharmacy, hospital or other person licensed, registered or otherwise
284 permitted by this state to distribute, dispense, conduct research with respect to or administer or
285 to use in teaching or chemical analysis, a controlled substance in the course of professional
286 practice or research in this state, or a pharmacy, hospital or other institution licensed, registered,
287 or otherwise permitted to distribute, dispense, conduct research with respect to or administer a
288 controlled substance in the course of professional practice or research;

289 [(36)] (37) "Production", includes the manufacture, planting, cultivation, growing, or
290 harvesting of drug paraphernalia or of a controlled substance or an imitation controlled
291 substance;

292 [(37)] (38) "Registry number", the number assigned to each person registered under the
293 federal controlled substances laws;

294 [(38)] (39) "Sale", includes barter, exchange, or gift, or offer therefor, and each such
295 transaction made by any person, whether as principal, proprietor, agent, servant or employee;

296 [(39)] (40) "State" when applied to a part of the United States, includes any state,
297 district, commonwealth, territory, insular possession thereof, and any area subject to the legal
298 authority of the United States of America;

299 [(40)] (41) "Synthetic cannabinoid", includes unless specifically excepted or unless
300 listed in another schedule, any natural or synthetic material, compound, mixture, or preparation
301 that contains any quantity of a substance that is a cannabinoid receptor agonist, including but not
302 limited to any substance listed in paragraph (II) of subdivision (4) of subsection 2 of section
303 195.017 and any analogues[,] ; homologues; isomers, whether optical, positional, or geometric;
304 esters; ethers; salts; and salts of isomers, esters, and ethers, whenever the existence of the
305 isomers, esters, ethers, or salts is possible within the specific chemical designation, however, it
306 shall not include any approved pharmaceutical authorized by the United States Food and Drug
307 Administration;

308 [(41)] (42) "Ultimate user", a person who lawfully possesses a controlled substance or
309 an imitation controlled substance for his own use or for the use of a member of his household
310 or for administering to an animal owned by him or by a member of his household;

311 [(42)] (43) "Wholesaler", a person who supplies drug paraphernalia or controlled
312 substances or imitation controlled substances that he himself has not produced or prepared, on
313 official written orders, but not on prescriptions.

195.017. 1. The department of health and senior services shall place a substance in
2 Schedule I if it finds that the substance:

3 (1) Has high potential for abuse; and

4 (2) Has no accepted medical use in treatment in the United States or lacks accepted
5 safety for use in treatment under medical supervision.

6 2. Schedule I:

7 (1) The controlled substances listed in this subsection are included in Schedule I;

8 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
9 of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these
10 isomers, esters, ethers and salts is possible within the specific chemical designation:

11 (a) Acetyl-alpha-methylfentanyl;

12 (b) Acetylmethadol;

13 (c) Allylprodine;

14 (d) Alphacetylmethadol;

15 (e) Alphameprodine;

16 (f) Alphamethadol;

17 (g) Alpha-methylfentanyl;

18 (h) Alpha-methylthiofentanyl;

19 (i) Benzethidine;

20 (j) Betacetylmethadol;

21 (k) Beta-hydroxyfentanyl;

- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxy;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;
- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;

- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphanol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myrophine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;
- 89 (u) Normorphine;
- 90 (v) Pholcodine;
- 91 (w) Thebacon;

92 (4) Any material, compound, mixture or preparation which contains any quantity of the
93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically

94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
95 the specific chemical designation:

- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (i) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;
- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
110 isomers;
- 111 (o) Alpha-ethyltryptamine;
- 112 (p) Alpha-methyltryptamine;
- 113 (q) Bufotenine;
- 114 (r) Diethyltryptamine;
- 115 (s) Dimethyltryptamine;
- 116 (t) 5-methoxy-N,N-diisopropyltryptamine;
- 117 (u) Ibogaine;
- 118 (v) Lysergic acid diethylamide;
- 119 (w) Marijuana or marihuana, **except industrial hemp as defined in section 195.010;**
- 120 (x) Mescaline;
- 121 (y) Parahexyl;
- 122 (z) Peyote, to include all parts of the plant presently classified botanically as Lophophora
123 Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
124 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
125 its seed or extracts;
- 126 (aa) N-ethyl-3-piperidyl benzilate;
- 127 (bb) N-methyl-3-piperidyl benzilate;
- 128 (cc) Psilocybin;
- 129 (dd) Psilocyn;

- 130 (ee) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
131 (cannabis plant), **except industrial hemp as defined in section 195.010**, as well as synthetic
132 equivalents of the substances contained in the cannabis plant, or in the resinous extractives of
133 such plant, or synthetic substances, derivatives, and their isomers with similar chemical structure
134 and pharmacological activity to those substances contained in the plant, such as the following:
- 135 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 136 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 137 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 138 d. Any compounds of these structures, regardless of numerical designation of atomic
139 positions covered;
- 140 (ff) Ethylamine analog of phencyclidine;
- 141 (gg) Pyrrolidine analog of phencyclidine;
- 142 (hh) Thiophene analog of phencyclidine;
- 143 (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 144 (jj) Salvia divinorum;
- 145 (kk) Salvinorin A;
- 146 (ll) Synthetic cannabinoids:
- 147 a. Any compound structurally derived from 3-(1-naphthoyl)indole or
148 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by
149 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl
150 or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
151 extent, whether or not substituted in the naphthyl ring to any extent. Including, but not limited
152 to:
 - 153 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
 - 154 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
 - 155 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
 - 156 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
 - 157 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
 - 158 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
 - 159 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
 - 160 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
 - 161 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
 - 162 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
 - 163 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
 - 164 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;

165 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the
166 nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
167 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
168 substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any
169 extent;

170 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution
171 at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
172 cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or
173 not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl
174 ring to any extent;

175 d. Any compound structurally derived from 3-phenylacetylindole by substitution at the
176 nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
177 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
178 substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any
179 extent. Including, but not limited to:

- 180 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
- 181 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
- 182 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
- 183 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
- 184 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;

185 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by
186 substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
187 cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or
188 not substituted in the cyclohexyl ring to any extent. Including, but not limited to:

- 189 (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-
190 yl)phenol), where side chain n=5, and homologues where side chain n-4,6, or 7;

191 f. Any compound containing a 3-(benzoyl)indole structure with substitution at the
192 nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
193 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
194 substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to
195 any extent. Including, but not limited to:

- 196 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
- 197 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;

198 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-
199 yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

- 200 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
201 6a,7,10,10 a-tetrahydrobenzo[c]chromen-1-ol;
- 202 i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
203 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- 204 j. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-
205 yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
- 206 k. Dimethylheptylpyran, or DMHP;
- 207 (5) Any material, compound, mixture or preparation containing any quantity of the
208 following substances having a depressant effect on the central nervous system, including their
209 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
210 isomers is possible within the specific chemical designation:
- 211 (a) Gamma-hydroxybutyric acid;
- 212 (b) Mecloqualone;
- 213 (c) Methaqualone;
- 214 (6) Any material, compound, mixture or preparation containing any quantity of the
215 following substances having a stimulant effect on the central nervous system, including their
216 salts, isomers and salts of isomers:
- 217 (a) Aminorex;
- 218 (b) N-benzylpiperazine;
- 219 (c) Cathinone;
- 220 (d) Fenethylamine;
- 221 (e) 3-Fluoromethcathinone;
- 222 (f) 4-Fluoromethcathinone;
- 223 (g) Mephedrone, or 4-methylmethcathinone;
- 224 (h) Methcathinone;
- 225 (i) 4-methoxymethcathinone;
- 226 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 227 (k) Methylenedioxypropylamphetamine, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-
228 pyrrolidinyl)-1-pentanone);
- 229 (l) Methylenedioxypropylamphetamine, or 3,4-Methylenedioxypropylamphetamine;
- 230 (m) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP;
- 231 (n) N-ethylamphetamine;
- 232 (o) N,N-dimethylamphetamine;
- 233 (7) A temporary listing of substances subject to emergency scheduling under federal law
234 shall include any material, compound, mixture or preparation which contains any quantity of the
235 following substances:

236 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
237 salts and salts of isomers;

238 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
239 optical isomers, salts and salts of isomers;

240 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
241 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
242 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

243 3. The department of health and senior services shall place a substance in Schedule II
244 if it finds that:

245 (1) The substance has high potential for abuse;

246 (2) The substance has currently accepted medical use in treatment in the United States,
247 or currently accepted medical use with severe restrictions; and

248 (3) The abuse of the substance may lead to severe psychic or physical dependence.

249 4. The controlled substances listed in this subsection are included in Schedule II:

250 (1) Any of the following substances whether produced directly or indirectly by extraction
251 from substances of vegetable origin, or independently by means of chemical synthesis, or by
252 combination of extraction and chemical synthesis:

253 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
254 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
255 nalmeferene, naloxone and naltrexone, and their respective salts but including the following:

256 a. Raw opium;

257 b. Opium extracts;

258 c. Opium fluid;

259 d. Powdered opium;

260 e. Granulated opium;

261 f. Tincture of opium;

262 g. Codeine;

263 h. Ethylmorphine;

264 i. Etorphine hydrochloride;

265 j. Hydrocodone;

266 k. Hydromorphone;

267 l. Metopon;

268 m. Morphine;

269 n. Oxycodone;

270 o. Oxymorphone;

271 p. Thebaine;

272 (b) Any salt, compound, derivative, or preparation thereof which is chemically
273 equivalent or identical with any of the substances referred to in this subdivision, but not
274 including the isoquinoline alkaloids of opium;

275 (c) Opium poppy and poppy straw;

276 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
277 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
278 with any of these substances, but not including decocainized coca leaves or extractions which
279 do not contain cocaine or ecgonine;

280 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
281 or powder form which contains the phenanthrene alkaloids of the opium poppy);

282 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
283 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
284 the specific chemical designation, dextrorphan and levopropoxyphene excepted:

285 (a) Alfentanil;

286 (b) Alphaprodine;

287 (c) Anileridine;

288 (d) Bezitramide;

289 (e) Bulk dextropropoxyphene;

290 (f) Carfentanil;

291 (g) Dihydrocodeine;

292 (h) Diphenoxylate;

293 (i) Fentanyl;

294 (j) Isomethadone;

295 (k) Levo-alphaacetylmethadol;

296 (l) Levomethorphan;

297 (m) Levorphanol;

298 (n) Metazocine;

299 (o) Methadone;

300 (p) Meperidine;

301 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

302 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, [1-diphenylpropane--carboxylic
303 acid] **1-diphenylpropane-carboxylic acid**;

304 (s) Pethidine (meperidine);

305 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

306 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;

307 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

- 308 (w) Phenazocine;
- 309 (x) Piminodine;
- 310 (y) Racemethorphan;
- 311 (z) Racemorphan;
- 312 (aa) Remifentanil;
- 313 (bb) Sufentanil;
- 314 (cc) Tapentadol;
- 315 (3) Any material, compound, mixture, or preparation which contains any quantity of the
- 316 following substances having a stimulant effect on the central nervous system:
- 317 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 318 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 319 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 320 (d) Phenmetrazine and its salts;
- 321 (e) Methylphenidate;
- 322 (4) Any material, compound, mixture, or preparation which contains any quantity of the
- 323 following substances having a depressant effect on the central nervous system, including its salts,
- 324 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
- 325 is possible within the specific chemical designation:
- 326 (a) Amobarbital;
- 327 (b) Glutethimide;
- 328 (c) Pentobarbital;
- 329 (d) Phencyclidine;
- 330 (e) Secobarbital;
- 331 (5) Any material or compound which contains any quantity of nabilone;
- 332 (6) Any material, compound, mixture, or preparation which contains any quantity of the
- 333 following substances:
- 334 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
- 335 (b) Immediate precursors to phencyclidine (PCP):
- 336 a. 1-phenylcyclohexylamine;
- 337 b. 1-piperidinocyclohexanecarbonitrile (PCC);
- 338 (7) Any material, compound, mixture, or preparation which contains any quantity of the
- 339 following alkyl nitrites:
- 340 (a) Amyl nitrite;
- 341 (b) Butyl nitrite.
- 342 5. The department of health and senior services shall place a substance in Schedule III
- 343 if it finds that:

344 (1) The substance has a potential for abuse less than the substances listed in Schedules
345 I and II;

346 (2) The substance has currently accepted medical use in treatment in the United States;
347 and

348 (3) Abuse of the substance may lead to moderate or low physical dependence or high
349 psychological dependence.

350 6. The controlled substances listed in this subsection are included in Schedule III:

351 (1) Any material, compound, mixture, or preparation which contains any quantity of the
352 following substances having a potential for abuse associated with a stimulant effect on the
353 central nervous system:

- 354 (a) Benzphetamine;
- 355 (b) Chlorphentermine;
- 356 (c) Clortermine;
- 357 (d) Phendimetrazine;

358 (2) Any material, compound, mixture or preparation which contains any quantity or salt
359 of the following substances or salts having a depressant effect on the central nervous system:

360 (a) Any material, compound, mixture or preparation which contains any quantity or salt
361 of the following substances combined with one or more active medicinal ingredients:

- 362 a. Amobarbital;
- 363 b. Secobarbital;
- 364 c. Pentobarbital;

365 (b) Any suppository dosage form containing any quantity or salt of the following:

- 366 a. Amobarbital;
- 367 b. Secobarbital;
- 368 c. Pentobarbital;

369 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
370 salt;

- 371 (d) Chlorhexadol;
- 372 (e) Embutramide;

373 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
374 a drug product for which an application has been approved under Section 505 of the federal
375 Food, Drug, and Cosmetic Act;

- 376 (g) Ketamine, its salts, isomers, and salts of isomers;
- 377 (h) Lysergic acid;
- 378 (i) Lysergic acid amide;
- 379 (j) Methyprylon;

- 380 (k) Sulfondiethylmethane;
- 381 (l) Sulfonethylmethane;
- 382 (m) Sulfonmethane;
- 383 (n) Tiletamine and zolazepam or any salt thereof;
- 384 (3) Nalorphine;
- 385 (4) Any material, compound, mixture, or preparation containing limited quantities of any
- 386 of the following narcotic drugs or their salts:
- 387 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 388 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
- 389 of opium;
- 390 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
- 391 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
- 392 therapeutic amounts;
- 393 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 394 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
- 395 isoquinoline alkaloid of opium;
- 396 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
- 397 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
- 398 ingredients in recognized therapeutic amounts;
- 399 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
- 400 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
- 401 recognized therapeutic amounts;
- 402 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
- 403 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
- 404 ingredients in recognized therapeutic amounts;
- 405 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
- 406 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
- 407 active nonnarcotic ingredients in recognized therapeutic amounts;
- 408 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
- 409 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
- 410 amounts;
- 411 (5) Any material, compound, mixture, or preparation containing any of the following
- 412 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;
- 413 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
- 414 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and
- 415 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is

416 expressly intended for administration through implants to cattle or other nonhuman species and
417 which has been approved by the Secretary of Health and Human Services for that administration.
418 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall
419 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the
420 meaning of this subdivision. Unless specifically excepted or unless listed in another schedule,
421 any material, compound, mixture or preparation containing any quantity of the following
422 substances, including its salts, esters and ethers:

- 423 (a) $3\beta,17$ -dihydroxy- 5α -androstane;
- 424 (b) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;
- 425 (c) 5α -androstan- $3,17$ -dione;
- 426 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);
- 427 (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);
- 428 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
- 429 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
- 430 (h) 1-androstenedione ($[5\alpha]$ -androst-1-en- $3,17$ -dione);
- 431 (i) 4-androstenedione (androst-4-en- $3,17$ -dione);
- 432 (j) 5-androstenedione (androst-5-en- $3,17$ -dione);
- 433 (k) Bolasterone ($7\alpha,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
- 434 (l) Boldenone (17β -hydroxyandrost-1,4,-diene-3-one);
- 435 (m) Boldione;
- 436 (n) Calusterone ($7\beta,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
- 437 (o) Clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);
- 438 (p) Dehydrochloromethyltestosterone (4-chloro- 17β -hydroxy- 17α -methyl-androst-1,4-
- 439 dien-3-one);
- 440 (q) Desoxymethyltestosterone;
- 441 (r) Δ^1 -dihydrotestosterone (a.k.a. '1-testosterone')(17β -hydroxy- 5α -androst-1-en-3-one);
- 442 (s) 4-dihydrotestosterone (17β -hydroxy-androstan-3-one);
- 443 (t) Drostanolone (17β -hydroxy- 2α -methyl- 5α -androstan-3-one);
- 444 (u) Ethylestrenol (17α -ethyl- 17β -hydroxyestr-4-ene);
- 445 (v) Fluoxymesterone (9-fluoro- 17α -methyl- $11\beta,17\beta$ -dihydroxyandrost-4-en-3-one);
- 446 (w) Formebolone (2-formyl- 17α -methyl- $11\alpha,17\beta$ -dihydroxyandrost-1,4-dien-3-one);
- 447 (x) Furazabol (17α -methyl- 17β -hydroxyandrostano[2,3-c]-furan);
- 448 (y) 13β -ethyl- 17β -hydroxygon-4-en-3-one;
- 449 (z) 4-hydroxytestosterone (4, 17β -dihydroxy-androst-4-en-3-one);
- 450 (aa) 4-hydroxy-19-nortestosterone (4, 17β -dihydroxy-estr-4-en-3-one);
- 451 (bb) Mestanolone (17α -methyl- 17β -hydroxy- 5α -androstan-3-one);

- 452 (cc) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
453 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
454 (ee) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
455 (ff) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
456 (gg) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane);
457 (hh) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane);
458 (ii) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
459 (jj) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-
460 one);
461 (kk) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
462 (ll) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9,11-trien-3-one);
463 (mm) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
464 (nn) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
465 (oo) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-
466 one) (a.k.a. '17- α -methyl-1-testosterone');
467 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
468 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
469 (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
470 (ss) 19-nor-4,9(10)-androstadienedione;
471 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
472 (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
473 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
474 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
475 (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
476 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
477 (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
478 (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
479 (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
480 (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
481 (ddd) Oxymethalone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstan-3-
482 one);
483 (eee) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
484 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
485 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
486 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
487 (iii) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);

- 488 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
489 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this
490 subdivision, except an anabolic steroid which is expressly intended for administration through
491 implants to cattle or other nonhuman species and which has been approved by the Secretary of
492 Health and Human Services for that administration;
- 493 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
494 United States Food and Drug Administration approved drug product;
- 495 (8) The department of health and senior services may except by rule any compound,
496 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
497 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
498 195.320 if the compound, mixture, or preparation contains one or more active medicinal
499 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
500 admixtures are included therein in combinations, quantity, proportion, or concentration that
501 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
502 the central nervous system.
- 503 7. The department of health and senior services shall place a substance in Schedule IV
504 if it finds that:
- 505 (1) The substance has a low potential for abuse relative to substances in Schedule III;
506 (2) The substance has currently accepted medical use in treatment in the United States;
507 and
- 508 (3) Abuse of the substance may lead to limited physical dependence or psychological
509 dependence relative to the substances in Schedule III.
- 510 8. The controlled substances listed in this subsection are included in Schedule IV:
- 511 (1) Any material, compound, mixture, or preparation containing any of the following
512 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
513 as set forth below:
- 514 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
515 of atropine sulfate per dosage unit;
- 516 (b) Dextropropoxyphene (α -(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
517 propionoxybutane);
- 518 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
519 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
520 upon the compound, mixture or preparation valuable medicinal qualities other than those
521 possessed by the narcotic drug alone:
- 522 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
523 one hundred grams;

524 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
525 or per one hundred grams;

526 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
527 or per one hundred grams;

528 (2) Any material, compound, mixture or preparation containing any quantity of the
529 following substances, including their salts, isomers, and salts of isomers whenever the existence
530 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 531 (a) Alprazolam;
- 532 (b) Barbitol;
- 533 (c) Bromazepam;
- 534 (d) Camazepam;
- 535 (e) Chloral betaine;
- 536 (f) Chloral hydrate;
- 537 (g) Chlordiazepoxide;
- 538 (h) Clobazam;
- 539 (i) Clonazepam;
- 540 (j) Clorazepate;
- 541 (k) Clotiazepam;
- 542 (l) Cloxazolam;
- 543 (m) Delorazepam;
- 544 (n) Diazepam;
- 545 (o) Dichloralphenazone;
- 546 (p) Estazolam;
- 547 (q) Ethchlorvynol;
- 548 (r) Ethinamate;
- 549 (s) Ethyl loflazepate;
- 550 (t) Fludiazepam;
- 551 (u) Flunitrazepam;
- 552 (v) Flurazepam;
- 553 (w) Fospropofol;
- 554 (x) Halazepam;
- 555 (y) Haloxazolam;
- 556 (z) Ketazolam;
- 557 (aa) Loprazolam;
- 558 (bb) Lorazepam;
- 559 (cc) Lormetazepam;

- 560 (dd) Mebutamate;
561 (ee) Medazepam;
562 (ff) Meprobamate;
563 (gg) Methohexital;
564 (hh) Methylphenobarbital (mephobarbital);
565 (ii) Midazolam;
566 (jj) Nimetazepam;
567 (kk) Nitrazepam;
568 (ll) Nordiazepam;
569 (mm) Oxazepam;
570 (nn) Oxazolam;
571 (oo) Paraldehyde;
572 (pp) Petrichloral;
573 (qq) Phenobarbital;
574 (rr) Pinazepam;
575 (ss) Prazepam;
576 (tt) Quazepam;
577 (uu) Temazepam;
578 (vv) Tetrazepam;
579 (ww) Triazolam;
580 (xx) Zaleplon;
581 (yy) Zolpidem;
582 (zz) Zopiclone;
583 (3) Any material, compound, mixture, or preparation which contains any quantity of the
584 following substance including its salts, isomers and salts of isomers whenever the existence of
585 such salts, isomers and salts of isomers is possible: fenfluramine;
586 (4) Any material, compound, mixture or preparation containing any quantity of the
587 following substances having a stimulant effect on the central nervous system, including their
588 salts, isomers and salts of isomers:
589 (a) Cathine ((+)-norpseudoephedrine);
590 (b) Diethylpropion;
591 (c) Fencamfamin;
592 (d) Fenproporex;
593 (e) Mazindol;
594 (f) Mefenorex;
595 (g) Modafinil;

- 596 (h) Pemoline, including organometallic complexes and chelates thereof;
597 (i) Phentermine;
598 (j) Pipradrol;
599 (k) Sibutramine;
600 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
601 (5) Any material, compound, mixture or preparation containing any quantity of the
602 following substance, including its salts:
603 (a) butorphanol;
604 (b) pentazocine;
605 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
606 is the only active medicinal ingredient;
607 (7) The department of health and senior services may except by rule any compound,
608 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
609 subsection from the application of all or any part of sections 195.010 to 195.320 if the
610 compound, mixture, or preparation contains one or more active medicinal ingredients not having
611 a depressant effect on the central nervous system, and if the admixtures are included therein in
612 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
613 substances which have a depressant effect on the central nervous system.
614 9. The department of health and senior services shall place a substance in Schedule V
615 if it finds that:
616 (1) The substance has low potential for abuse relative to the controlled substances listed
617 in Schedule IV;
618 (2) The substance has currently accepted medical use in treatment in the United States;
619 and
620 (3) The substance has limited physical dependence or psychological dependence liability
621 relative to the controlled substances listed in Schedule IV.
622 10. The controlled substances listed in this subsection are included in Schedule V:
623 (1) Any compound, mixture or preparation containing any of the following narcotic
624 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
625 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
626 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
627 qualities other than those possessed by the narcotic drug alone:
628 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
629 twenty-five micrograms of atropine sulfate per dosage unit;
630 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
631 one hundred grams;

632 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
633 micrograms of atropine sulfate per dosage unit;

634 (2) Any material, compound, mixture or preparation which contains any quantity of the
635 following substance having a stimulant effect on the central nervous system including its salts,
636 isomers and salts of isomers: pyrovalerone;

637 (3) Any compound, mixture, or preparation containing any detectable quantity of
638 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
639 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
640 isomers, or salts of optical isomers;

641 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
642 material, compound, mixture, or preparation which contains any quantity of the following
643 substances having a depressant effect on the central nervous system, including its salts:

644 (a) Lacosamide;

645 (b) Pregabalin.

646 11. If any compound, mixture, or preparation as specified in subdivision (3) of
647 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
648 prescription:

649 (1) All packages of any compound, mixture, or preparation containing any detectable
650 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
651 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
652 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
653 registered pharmacy technician; and

654 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
655 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
656 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
657 shall be at least eighteen years of age; and

658 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
659 any person, prior to [their] **such person's** purchasing, receiving or otherwise acquiring such
660 compound, mixture, or preparation to furnish suitable photo identification that is issued by a state
661 or the federal government or a document that, with respect to identification, is considered
662 acceptable and showing the date of birth of the person;

663 (4) The seller shall deliver the product directly into the custody of the purchaser.

664 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
665 implement and maintain an electronic log of each transaction. Such log shall include the
666 following information:

667 (1) The name, address, and signature of the purchaser;

- 668 (2) The amount of the compound, mixture, or preparation purchased;
669 (3) The date and time of each purchase; and
670 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
671 technician who dispensed the compound, mixture, or preparation to the purchaser.
- 672 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
673 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
674 transmission methods and frequency established by the department by regulation;
- 675 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
676 greater than those specified in this chapter.
- 677 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
678 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
679 where the public is not permitted.
- 680 16. Any person who knowingly or recklessly violates the provisions of subsections 11
681 to 15 of this section is guilty of a class A misdemeanor.
- 682 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
683 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
684 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
685 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
686 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.
- 687 18. The manufacturer of a drug product or another interested party may apply with the
688 department of health and senior services for an exemption from this section. The department of
689 health and senior services may grant an exemption by rule from this section if the department
690 finds the drug product is not used in the illegal manufacture of methamphetamine or other
691 controlled or dangerous substances. The department of health and senior services shall rely on
692 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
693 proposed product can be used to manufacture illicit controlled substances.
- 694 19. The department of health and senior services shall revise and republish the schedules
695 annually.
- 696 20. The department of health and senior services shall promulgate rules under chapter
697 536 regarding the security and storage of Schedule V controlled substances, as described in
698 subdivision (3) of subsection 10 of this section, for distributors as registered by the department
699 of health and senior services.
- 700 21. Logs of transactions required to be kept and maintained by this section and section
701 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
702 the person whose transactions are recorded in the logs.

195.202. 1. Except as authorized by sections 195.005 to 195.425, it is unlawful for any person to possess or have under his control a controlled substance.

2. Any person who violates this section with respect to any controlled substance except thirty-five grams or less of marijuana or any synthetic cannabinoid is guilty of a class C felony.

3. Any person who violates this section with respect to not more than thirty-five grams of marijuana or any synthetic cannabinoid is guilty of a class A misdemeanor.

4. In any case where the defendant claims that the substance possessed was industrial hemp and not a controlled substance the burden of proof shall be on the defendant to prove that the substance was industrial hemp and not a controlled substance.

195.203. Notwithstanding any other provision of this chapter it shall be legal for any person who has not been convicted of any felony offense or any misdemeanor drug related offense to grow and cultivate industrial hemp as defined in section 195.010.

195.600. For the purposes of sections 195.600 to 195.606, the following words shall mean:

(1) “Agricultural hemp seed”, Cannabis Sativa seed that meets any labeling, quality or other standards set by the department of agriculture and that is intended for sale, is sold to, or is purchased by licensed growers for planting;

(2) “Crop”, any contiguous field of industrial hemp grown under a single license;

(3) “Grower”, a person, joint venture, or cooperative that produces industrial hemp;

(4) “Handler”, a person, joint venture, or cooperative that receives industrial hemp for processing into commodities, products, or agricultural hemp seed;

(5) “Industrial hemp”, as that term is defined in section 195.010.

195.603. 1. Industrial hemp production, possession and commerce in industrial hemp commodities and products shall be permitted in this state.

2. Industrial hemp shall be an agricultural product that is subject to regulation by the department of agriculture, and any grower and handler of industrial hemp shall obtain a license from the department. Growers and handlers engaged in the production of agricultural hemp seed also shall have an agricultural hemp seed production permit.

3. An application for an industrial hemp license or agricultural hemp seed production permit shall include:

(1) The name and address of the applicant;

(2) The name and address of the industrial hemp operation of the applicant;

(3) The global positioning system coordinates and legal description for the property used for the industrial hemp;

13 (4) If the industrial hemp license or agricultural hemp seed production permit
14 application is by the grower, information sufficient to establish that the industrial hemp
15 crop of the applicant will be at least two and one-half acres in size; and

16 (5) Any other information required by the department.

17 4. An industrial hemp license or agricultural hemp seed production permit is non-
18 transferable and valid for a three-year term unless revoked by the department and may
19 be renewed as determined by the department.

20 5. An agricultural hemp seed production permit authorizes a grower or handler to
21 produce and handle agricultural hemp seed for sale to licensed industrial hemp growers
22 and handlers. The department shall make information that identifies sellers of agricultural
23 hemp seed available to growers, and any seller of agricultural hemp seed shall ensure that
24 the seed complies with any standards established by the department.

25 6. A grower may retain seed from each industrial hemp crop to ensure a sufficient
26 supply of seed for that grower for the following year. He or she shall not be required to
27 obtain an agricultural hemp seed production permit in order to retain seed for future
28 planting. Any seed retained by a grower for future planting shall not be sold or
29 transferred and does not have to meet agricultural hemp seed standards established by the
30 department.

31 7. Every grower or handler shall keep industrial hemp crop and agricultural hemp
32 seed records as required by the department. Upon three days' notice, the department may
33 require an inspection or audit during any normal business hours for the purpose of
34 ensuring compliance with:

35 (1) Any provision of this chapter;

36 (2) Department rules and regulations;

37 (3) Industrial hemp license or agricultural hemp seed production permit
38 requirements, terms, or conditions; or

39 (4) A final department order directed to the grower's or handler's industrial hemp
40 operations or activities.

41 8. In addition to any inspection conducted pursuant to subsection 7 of this section,
42 the department may inspect any industrial hemp crop during the crop's growth phase and
43 take a representative composite sample for field analysis. If a crop contains an average
44 tetrahydrocannabinol concentration exceeding three-tenths of one percent on a dry weight
45 basis, the department may detain, seize, or embargo the crop.

46 9. The department may charge growers and handlers reasonable fees as determined
47 by the department. Moneys from fees charged under this subsection shall be continuously

48 appropriated to the department for the purpose of carrying out the duties of the
49 department under sections 195.600 to 195.606.

50 **10.** The department of agriculture may promulgate any rule or regulation
51 necessary to administer the provisions of this section and section 195.606. Any rule or
52 portion of a rule, as that term is defined in section 536.010, that is created under the
53 authority delegated in this section shall become effective only if it complies with and is
54 subject to all of the provisions of chapter 536 and, if applicable, section 536.028. This
55 section and chapter 536 are nonseverable, and if any of the powers vested with the general
56 assembly under chapter 536 to review, to delay the effective date, or to disapprove and
57 annul a rule are subsequently held unconstitutional, then the grant of rulemaking
58 authority and any rule proposed or adopted after August 28, 2014, shall be invalid and
59 void.

195.606. 1. The department of agriculture may revoke or refuse to issue or renew
2 an industrial hemp license or agricultural hemp seed production permit and may impose
3 a civil penalty, not to exceed two thousand five hundred dollars, for violation of:

- 4 **(1)** A license or permit requirement;
5 **(2)** License or permit terms or conditions;
6 **(3)** Department rules relating to growing or handling industrial hemp; or
7 **(4)** A final order of the department that is specifically directed to the grower's or
8 handler's industrial hemp operations or activities.

9 **2.** In addition, the department may revoke or refuse to issue or renew an industrial
10 hemp license or an agricultural hemp seed production permit for violation of any rule of
11 the department that pertains to agricultural operations or activities other than industrial
12 hemp growing or handling.

✓